There are over 15,000 known variants that cause human inherited disease by disrupting RNA splicing. While several in silico methods such as CADD, EIGEN and LINSIGHT are commonly used to predict the pathogenicity of noncoding variants, we introduce S-CAP, a tool developed specially for splicing which is better able to effectively distinguish pathogenic splicing-relevant variants from benign variants. S-CAP is a novel splicing pathogenicity predictor that reduces the number of splicing-relevant variants of uncertain significance in patient exomes by 41%, a nearly 3-fold improvement over existing noncoding pathogenicity measures while correctly classifying known pathogenic splicing-relevant variants with a clinical-grade 95% sensitivity.
Introduction
Genomic sequencing, and in particular exome sequencing, is revolutionizing the diagnosis of Mendelian disease [1] [2] [3] [4] , with over 5,000 genetic diseases already successfully mapped to over 3,000 genes 5 . Sifting through patient exomes in search of a causal variant is a time consuming process that often focuses on the coding sequence (CDS) of genes 6, 7 . Powerful pathogenicity meta-predictors such as M-CAP 8 integrate multiple primary predictors such as SIFT 9 , Polyphen-2 10 and CADD 11 with cross-species sequence conservation features to offer accurate clinical grade predictions capable of missing only a tiny fraction of known coding pathogenic mutations 12 . Achieving high sensitivity is important because reducing the size of the candidate list of variants of uncertain significance (VUS) is futile if the pathogenic variant itself is incorrectly classified as benign 13 . M-CAP is commonly used by clinicians to prioritize nonsynonymous variants 14, 15 , so that they can effectively consider first the variants that are most likely to yield a diagnosis. However, with estimates that 70% of patient cases remain undiagnosed 16, 17 , there is value in looking beyond the CDS itself. Splicing is a complex and crucial step of gene expression, wherein vast sections of RNA, called introns, are removed from a pre-messenger RNA and the remaining RNA, called exons, are joined together to form the mature messenger RNA (mRNA). Changes in splicing induced by genetic variants can have severe impacts on the protein coding potential of an mRNA, such as the exclusion of an entire exon 18 or a frameshift 19, 20 induced by creation of a new splice site 21 , among other effects 22-2422-24 . Exome sequencing typically captures sequence information up to 50 base pairs past exon boundaries into each adjacent intron 25 . This region covers a broad class of splicing-relevant variants: those that disrupt existing splice sites or exonic and proximal intronic splicing regulators, such as the branch point, and some that create new splice sites.
Indeed, there are over 15,000 known Mendelian disease causing variants that impact the gene product through RNA splicing 26, 27 . At the same time, a typical singleton patient's exome contains over 500 splicing-relevant variants of uncertain significance (VUS) 28 . Existing tools such as CADD 11 , EIGEN 29 and LINSIGHT 30 tackle a broad spectrum of non-coding variants, but in doing so they do not effectively predict splicing-relevant variant pathogenicity or provide clinical grade assurances of minimizing the false prediction of known pathogenic splicing-relevant variants as benign. Generic methods ignore the rich literature characterizing mRNA splicing and predicting associated molecular phenotypes, such as the percentage-spliced-in of exons [31] [32] [33] [34] . These findings and methods provide invaluable insight into the potential of a variant to disrupt splicing. However, the splicing literature does not tell the whole story either, as predicting molecular phenotypes is a fundamentally different task from predicting if a variant will cause a disease. For a variant to cause a disease, the variant must disrupt normal splicing in one or more relevant tissues and the induced change in mRNA phenotype must be pathogenic. Similar obstacles are met in the few cases where clinicians attempt to identify patient genetic variants that disrupt splicing by performing a costly and time consuming RNA-seq experiment in an accessible, but not necessarily disease relevant, cell population 35, 36 . We introduce S-CAP (Splicing Clinically Applicable Pathogenicity), a machine learning tool that integrates knowledge of splicing with measures of variant, exon and gene importance into a splicingspecific pathogenicity score. We evaluate S-CAP at the high sensitivity required in clinical settings and show that it far outperforms existing non-coding pathogenicity scores, as well as tools focused solely on identifying synonymous variants that disrupt splicing. S-CAP will allow clinicians to consider a broad class of splicing-relevant variants, resulting in the diagnosis of more patients suffering from Mendelian disease.
Results
We developed a machine-learning framework to model and evaluate splicing-relevant variant pathogenicity. We analyzed the positional distribution and potential functional effects of variants near splice sites and defined 6 genomic regions that display distinct mutation rates and functional effects. We trained 6 models (1 per region) to predict splicing variant pathogenicity. This involved building (i) a labeled dataset of known pathogenic and benign splicing-relevant variants, (ii) a set of features to help discriminate between the pathogenic and benign variants in each region and (iii) a learning algorithm to identify patterns in the features and to distinguish between variants in the two classes. Finally, we evaluated our models on a set of known pathogenic and benign variants, as well as on real patients with various diseases caused by splicing-relevant variants.
The landscape of splice region variation
To build a dataset of labeled splicing-relevant variants, we considered variant pathogenicity, semantic effect and population frequency. We start by taking the union of 109,279 pathogenic single nucleotide variants (SNVs) from the Human Gene Mutation Database 26 (HGMD) and 25,793 pathogenic SNVs from ClinVar 37 to get a total of 114,382 unique pathogenic variants. We curated 15,833,389 benign SNVs observed in controls from the gnomAD database 38 who generally do not suffer from a Mendelian disease. To identify a subset of variants with a likely splicing semantic effect, these sets were filtered to the 'splicing region', all synonymous or intronic variants within 50 base pairs 25, 39 of an exon boundary (we justify the choice of 'splicing region' below). Removing nonsynonymous and loss of function (stop gain or stop loss) variants ensured that our model was trained and evaluated nearly exclusively on splicing-relevant variants. To avoid any ambiguities, the benign SNVs were further filtered to remove any variant labelled pathogenic in HGMD or ClinVar. This resulted in 14,938 splicing-relevant pathogenic variants and 7,027,609 splicing-relevant benign variants. Then a frequency filter, based on the ACMG guidelines 13 that suggest clinicians consider common (> 1% frequency) variants as definitively benign, was applied to both sets yielding 14,838 rare splicing-relevant pathogenic variants and 6,760,450 rare splicing-relevant benign variants. In support of this ACMG guideline, we note that only 100 of 14,938 (0.67%) known pathogenic variants in the splicing region are common in the general population (see Methods) .
To substantiate that nearly all pathogenic 'splicing region' variants do, in fact, disrupt splicing, we developed a simple model to assign a putative effect of variants on splicing. Variants can affect splicing by (1) create a cryptic splice site (2) disrupt an existing splice site or (3) disrupt an existing branchpoint, a mechanistically essential sequence motif generally located 18 to 45 base pairs upstream of each 3'SS 40 . We used the existing tools MaxEntScan 41 and LaBranchoR
42
, which predict the strength of splice site sequences and branchpoint sequences, respectively. We denoted a variant as creating a cryptic splice site if the variant creates a splice site with a MaxEntScan score at least as high as the score for the reference splice site (with the variant included), disrupting a splice site if it greatly reduces the MaxEntScan score of the reference splice site, and disrupting a branchpoint if it has a low LaBranchoR in silico mutagenesis score. In cases where a variant had multiple putative effects, e.g. creating a cryptic splice site and disrupting an existing splice site, we resolved to the most extreme effect (cryptic splice site creation > splice site disruption > branchpoint disruption). We found that 97% of pathogenic splicing-region variants are predicted to have an effect on splicing, as opposed to only 18% of likely benign variants (Fig. 1a-b) . We found that pathogenic variants are enriched at positions where the mechanistically essential U2 snRNA, U2AF, and U1 snRNA bind 43 (Fig. 1b) . Conversely, variants occurring in the general population are biased away from these high information content positions 44 (Fig. 1a) .
Region specific models to increase performance and alleviate ascertainment bias
In order to effectively capture these position specific patterns, we separated the variants into 6 regions relative to the splice sites with generally homogenous function and built a separate model for each region (Supplementary Fig. 1 ). Specifically, we grouped variants occurring in the obligate 5' GT (5' core) and 3' AG (3' core) dinucleotides, intronic variants upstream of a 3'ss (3' intronic), variants lying in the canonical U1 snRNA binding site, excluding the core 5'ss (5' extended), intronic variants downstream of a 5'ss (5' intronic), and synonymous variants within the protein coding gene (exonic) (Fig. 1c) .
Core splice site variants are well known as having a large functional effect and are readily identified, a fact that has likely led to an overrepresentation of core splice site variants in pathogenic variant databases. Around 73% of known splicing region pathogenic variants occur within the core splice sites (Fig. 1c) . Although this is consistent with the mechanistic importance of these positions, in unbiased studies of splicing quantitative trait loci, it is generally found that fewer than 1% of splicingrelevant variants are found to be located in core splice sites 45, 46 and in a recent study employing RNAseq data to identify splicing-relevant variants resulting in Mendelian disease only 2 of 6 (33%) causal variants in the splicing region were in core splice sites 35 . If left unaddressed, this bias would allow a classifier to have strong test set performance (by calling most core splice site variants pathogenic and others benign), but would often miss non-core splice site pathogenic variants. Separating variants by position allows us to guarantee that pathogenic variants are rarely misclassified as benign regardless of genomic region, thereby ensuring an overall low false negative rate irrespective of ascertainment biases present in annotated data.
S-CAP features
We curated existing metrics and developed several novel features to help distinguish between pathogenic and benign variants within the splicing region (Supplementary Table 1 ). The set consists of chromosome, gene, exon, and variant level features. At the chromosome level, 3 binary features distinguish between variants found on chromosome X, chromosome Y and the autosomes. Variants on the X chromosome present an important subset since in males, a hemizygous X chromosome variant inducing loss of function results in no viable gene product. Consistent with this intuition, pathogenic variants are highly enriched on the X chromosome as compared to the autosomes (7.11 fold enrichment, p < 10 -140 by two-sided Fisher's Exact Test). At the gene level, pLI 44 , RVIS 47 , and a haploinsufficiency score 48 help to measure the likelihood that a given gene is a 'disease gene'. At the exon level, exon length, exon length modulo 3, reference splice site strengths, an existing regional constraint score 49 and the exon sequence similarity between hg19 and 99 species from the UCSC 100way alignment serve to assist in distinguishing critical exons from those that may be safely excluded. Additionally, we developed a novel splice site constraint score to measure the fragility and tolerance of each exon to splice site mutations (see Online Methods). At the variant level, CADD 11 measures pathogenicity based on functional data annotations, LINSIGHT 30 measures variants' fitness effect through functional data and molecular evolution and SPIDEX 33 was incorporated to measure the impact of a variant on exon inclusion. PhyloP 50 and PhastCons 51 scores from the multiz46way and multiz100way alignments 52 measure the evolutionary importance of the affected base across primate species, placental mammals and all vertebrates. We also included a feature to capture the change in 3-mer content induced by a variant 53 . Additionally, we included region-specific features, such as a branchpoint disruption term for the 3' intronic region 42 and a 5' cryptic splice site creation term for the 5' intronic region (see Online Methods for a complete description of features).
The machine learning algorithm
Similar to the M-CAP classifier 8 for nonsynonymous SNVs, S-CAP is built using a gradient boosting tree classifier, a highly effective machine learning model 54 . This model iteratively builds decision trees, where each tree is picked to correct the most cases that were misclassified in the previous step. The final classifier is a linear combination of each of the previously derived decision trees (see Online Methods for details).
S-CAP consistently outperforms existing pathogenicity scores
Each of the 6 regions (described above) contains a set of pathogenic and benign variants (Fig. 1c) , which were used to train 6 separate models. We performed 5-fold cross-validation and selected the median performing model as the final model for each region. S-CAP was evaluated against the most popular existing methods that score splicing-relevant variants: CADD, SPIDEX, LINSIGHT and EIGEN. The 6 S-CAP models outperformed all existing methods in all regions resulting in up to a 26.6% improvement in the AUC over the next best performing model (Fig. 2) . S-CAP performance ranged from achieving an AUC of 0.804 in the 3' core region (Fig. 2b) to achieving an AUC of 0.953 in the 3' intronic region (Fig. 2a) . No existing method consistently outperforms the other existing metrics across all splicing regions (Fig. 2) .
To ensure a fair comparison, S-CAP performance on exonic variants was also independently compared against MutPred Splice 53 , a tool focused on scoring only splicing-relevant synonymous variants, and found superior in both AUC and especially hsr-AUC (see Online Methods and Supplementary Fig. 2 ).
Clinically relevant threshold maintains high sensitivity
As previously shown in M-CAP 8 , it is important to tune thresholds for clinical settings so that fewer than 5% of known pathogenic variants are misclassified. Neither LINSIGHT, EIGEN or SPIDEX provides a default threshold to consider a variant as pathogenic. As a result, it is difficult to use these methods for variant pathogenicity classification. CADD provides a threshold but, at the author-recommended default threshold, virtually all pathogenic splicing mutations outside the two core splice sites are discarded and incorrectly classified as benign ( Table 1) . Similarly, MutPred Splice provides a default threshold, but over 48% of known pathogenic exonic variants are misclassified at this threshold. We generated a high sensitivity threshold for all metrics in each region by finding the lowest threshold that results in the correct classification of at least 95% of a test set of pathogenic variants from that region ( Table 2) .
S-CAP is the best performer at clinically relevant thresholds
Moving into the high sensitivity domain, at or above a 95% true positive rate, S-CAP's performance ( Supplementary Fig. 3a-f ) ranged from achieving an hsr-AUC of 0.186 in the exonic region ( Supplementary Fig. 3c ) to an hsr-AUC of 0.549 in the 3' intronic region (Supplementary Fig. 3a) . Similarly, S-CAP outperforms MutPred Splice on an independent test set of exonic variants ( Supplementary Fig. 2b ). Overall, S-CAP improves on existing metrics in all 6 splicing regions when focused on the high sensitivity domain, and no existing method consistently outperforms the others .
Different patterns observed for recessive and dominant variants
Recessive and dominant diseases are associated with different selective pressure on alleles, which we hypothesized would result in different feature importance and thresholds for determining variant pathogenicity. To address this complexity, we developed separate classifiers for dominant (heterozygous in patient) and recessive (homozygous or compound heterozygous in patient) at the gene level. In patients, we are given whether each variant appears in the heterozygous or homozygous state. However, our training data did not provide dominant and recessive labels, so we developed a framework for predicting this information from a control population for the sake of model training (see Methods).
Tagging 3' and 5' core variants as dominant or recessive resulted in improved performance Supplementary Fig. 4a-h ) compared to models without these tags (Fig. 2b,d ). For 3' core variants, we built a model that improved upon an AUC of 0.804 and hsr-AUC of 0.257 from the original 3' Core model to an AUC of 0.805 and 0.890 ( Supplementary Fig. 4c,d ) and hsr-AUC of 0.296 and 0.454 ( Supplementary Fig. 4g,h ) when tested on just dominant or recessive variants, respectively. Similarly, for 5' core variants, we built a model that improves upon an AUC of 0.805 and hsr-AUC of 0.291 from the original 5' core model to an AUC of 0.779 and 0.880 (Supplementary Fig. 4a,b) and hsr-AUC of 0.222 and 0.518 (Supplementary Fig. 4e,f) when testing on just dominant or recessive variants, respectively. The S-CAP model to be used on patients takes advantage of these split dominant and recessive models in the core splice site regions.
S-CAP eliminates the most VUS in patient exomes
Resources like S-CAP are developed on large sets of benign and pathogenic variants but ultimately are used to help with the interpretation of VUS in individual patients (Fig. 1c) . To demonstrate the practical utility of S-CAP, we evaluated S-CAP and each of the comparison methods on 14 patients with Mendelian diseases caused by splice-altering mutations. After applying the standard allele frequency filter of ≤ 1%, a typical individual has on average a total of 533 rare variants within the splicing region (Fig. 1c) . Typically, ~32% of variants were observed in each of the 5' intronic, exonic and 3' intronic regions. 3% were in the 5' extended regions and 0-3 variants were in each of the 3' core and 5' core regions (Fig. 1c) . Existing methods, CADD, LINSIGHT, EIGEN and SPIDEX, using the 95% sensitivity thresholds ( Table 2) , perform comparably when applied to all VUS in the splicing region of an individual patient and on average reduce the number of VUS by 4% -15%. By contrast, S-CAP is more powerful, reducing the number of VUS in the splicing region for an individual patient by 31-46% (Fig. 3c) , while confidently retaining the pathogenic variant for further detailed analysis ( Table 3) . For a larger sample size, we also evaluated each method on all (n=2054) individuals in the 1000 Genomes Project 28 , which can conceptually be thought of as Mendelian disease patients with their pathogenic variants removed (see Fig. 1c ). The observed fraction of VUS reduced on average per 1000 Genomes Project individual is consistent with the performance observed when applied to patients (Fig. 3c-d) . Specifically, S-CAP is nearly three times as powerful as existing methods and on average results in a 41% reduction of the VUS within the splicing region of a given individual.
Discussion
Variants affecting splicing comprise the second largest category of known pathogenic mutations 27 . A broad class of potential splicing-relevant variants are already being captured by exome sequencing, yet clinicians are less able to interpret these variants for lack of proper interpretation tools. Here we address this problem by developing S-CAP, the first clinically applicable pathogenicity predictor dedicated exclusively to splicing-relevant variants.
In order for an in silico pathogenicity predictor to be useful in the clinic, it needs to be easy to use, carefully evaluated at high sensitivity and confidently remove a substantial fraction of benign variants. Existing noncoding variant tools are not easy to use for splicing variants because their performance is strongly dependent upon position relative to splice sites and no single method consistently outperforms the others. This means that employing existing methods, a clinician would have to consult multiple pathogenicity scores for variants in different regions. Furthermore, none of the existing methods have been carefully evaluated at clinical-grade sensitivity and most methods give no guidance about what cutoff should be used or result in the misclassification of an unacceptably high number of pathogenic variants ( Table 1) . After carefully evaluating the existing methods, we found that none of them confidently removed a considerable fraction of benign variants (Fig. 3) . For example, after we retuned it ( Table 2) , SPIDEX performed well on variants in the intronic bins, but was close to random at predicting the pathogenicity of core splice site variants. CADD, only after we retune it, ( Table 1 ,2) performed well on core and exonic variants but poorly on intronic variants (Fig. 2) . S-CAP, addresses these important issues, as it consistently outperforms existing methods across all the regions, its performance has been carefully evaluated at clinical-grade sensitivity, and it removes close to three times as many benign variants as any other method (Fig. 3) .
Central to the design of S-CAP is the use of region-specific models to alleviate the effects of ascertainment biases in curated pathogenic variant databases. Curated pathogenic variant databases contain invaluable information about the properties of pathogenic variants, but they also over-represent variants in known disease genes and in association with easily identifiable features. Of particular concern in splicing pathogenicity prediction is the inflated number of variants in core splice sites, which exists because they are easily recognized and have well established molecular consequences. If left unaddressed, this bias in the labeled pathogenic data would lead to unrealistic model performance, as a model could achieve relatively high test set performance simply by predicting that all core splice site variants are pathogenic and all others are benign. However, in the clinic, such a model would incorrectly classify pathogenic, non-core splice site variants as benign at an unacceptably high rate. Introducing separate models for each region alleviates this concern since each model's performance is evaluated using data from the same region, thereby assuring high sensitivity irrespective of the underlying positional distribution of pathogenic variants. Additionally, we accounted for the over-representation of pathogenic variants in known disease-associated genes by ensuring that variants from the same gene were never split between the training and evaluation sets (see Methods). This guaranteed that no gene level information was shared by features across folds.
The use of patient RNA-sequencing (RNA-seq) data to identify pathogenic variants that disrupt splicing is a growing and promising field 35, 36, 55 to which we believe S-CAP is complementary. In fact, our model already includes scores from SPIDEX 33 , a deep learning model that was trained on tissue-specific RNA-seq data to predict the change in percent spliced-in ( ) of an exon given a variant. It would only be a small step to supplement these predicted s with experimentally measured s from RNA-seq experiments. Observing through RNA-seq bypasses the difficult problem of explicitly or implicitly predicting the effect of a given variant on splicing in a particular cell type, but this is only part of the problem. Whether predicted or measured, gene expression and values vary between cell contexts and time points and in many cases the most relevant cell population to sequence would not be clear 36, 56 . Perhaps even more importantly, molecular phenotypes are multiple steps away from real phenotypic change, making it difficult to predict organismal pathogenicity from molecular phenotype 57 . These factors limit the direct applicability of observed or predicted s to cases where there is a good understanding of the relationship between a disease, the cell population it affects, and the set of potentially causative genes. Many of the features used by S-CAP, such as evolutionary conservation, implicitly integrate an allele's importance over all cell populations and time points, complementing the strengths of RNA-seq based methods. Another direction for the integration of S-CAP and experimental methods is the use of cheap and fast site-directed sequencing in a diverse array of cell types to validate putatively pathogenic sites identified by S-CAP 58 .
Eventually, comprehensive analysis of the splicing region will become commonplace in clinical settings. This is currently a difficult task given the complexity of splicing and the difficulty in predicting whether a change in splicing will result in disease. There are over five hundred rare variants of uncertain significance per individual in the splicing region with no clear semantic effect outside of the core splice sites and most are not observed in control populations. S-CAP represents an important step towards effectively interpreting splicing variation, but we will have to continue to improve on these methods, learning more from RNA-seq experiments, to render this problem more tractable. 
Online Methods

Variant Processing
Dataset of pathogenic and benign variants
Variant Annotation
ANNOVAR 59 v527 was used to annotate variants with predicted effect on protein-coding genes using gene isoforms from Ensembl 60 gene set version 75 for the hg19/GRCh37 assembly of the human genome. All coding isoforms were used where the transcript start and end sites were marked as complete and the coding span was a multiple of three.
Variant Filtering
All variants were filtered so as to only include rare variants in the splicing region that do not directly affect the protein coding sequence. Rare variants are defined to be variants with an allele frequency of 1% or less in all control populations and subpopulations in KGP phase 3, ExAC v0.3.1 and gnomAD r2.0.2. Variants in the splicing region that do not affect protein coding sequence are those determined to be synonymous or in the core splicing, extended splicing or intronic regions.
Positional Subsetting of Variants
Variants at different positions relative to splice sites have different properties, such as distributions of sequence conservation and ratio of pathogenic variants to benign variants. To better understand the relationship between position relative to splice site and the mechanistic effects on splicing, we developed a simple model to assign a putative effect of variants on splicing. To identify variants that create cryptic splice sites, we scanned a window the width of the MaxEntScan 41 input for the highest scoring splice site that is not the reference and reported the variant as creating a cryptic splice site if this highest scoring site was stronger than the reference (with the alternative allele included) and is made stronger by the variant. Variants that result in a decrease the MaxEntScan score of the reference splice site by 1 or more were determined to disrupt an existing splice sites. Finally, variants that have a LaBranchoR 42 in silico mutagenesis score of less than -0.1 were determined to disrupt a branchpoint. This led us to allocate variants into subsets based upon their position relative to splice sites and train separate models for each. Subsets were selected so as to group together functionally related positions. In total, we constructed 6 subsets (Fig. 1) . We created subsets of 3' and 5' core (1 or 2 bases from the splice site), extended (1-2 bases into the exon on the 5' side and 3 to 6 bases from the 5' splice site), 3' intronic (2 to 50 bases from the splice site), 5' intronic (7-50 bases from the 5' splice site) and exonic (inside the exon but outside the extended region) regions.
We associated each variant with a neighboring exon. For variants close to multiple exons, we attempted to assign the variant to the exon considered as having the highest chance of a pathogenic effect, which we inferred from the density of pathogenic variants in each bin. Specifically, we favored associations in the following order: core, 5' extended, intronic, and exonic.
Features
Our models utilized a diverse library of previously described and novel features ( fig. S1 ). These can be divided into gene level, exon level, and variant level features as well as a few features that are specific to individual regions. Below, we introduce our novel features and describe how we curated previously described features.
Gene Level
We obtained RVIS 47 scores from, the appropriately named, genic-intolerance.org (see URLs). We used the data in column "RVIS[pop_maf_0.05%(any)]" as a feature in our models. We obtained pLI 44 scores from supplementary table 13 of the original publication on 7 April 2017. We used as a feature the column denoted as pLI. We obtained a haploinsufficiency score 48 which is a probability of a gene being haploinsufficient directly from the publication page on the PLOS website in May 2017. We downloaded MPC, a recently proposed regional constraint score 49 (see URLs).
Exon Level
For each exon, we created splice site features which measure the number of rare and common variants observed in gnomAD in the 5' and 3' core (0-2) and extended (2-6) regions. This was motivated by the desire to share information between functionally similar positions. We take this feature to represent the constraint on the exon's splicing region in the human population. To avoid data leakage, when constructing this feature for a particular variant, we masked the effect of the variant itself on this score. Specifically, if a given 5'ss had one associated core variant, it was assigned a count of 0. If it had 2, both were assigned a count of 1. Additionally, we measured exon identity across vertebrates and found that the exon identities in many organisms were highly correlated. Principal components analysis (PCA) of the identity scores for all exons showed that 5 components explain the vast majority of variation in the data. To prevent overfitting, we included the original exon identities projected onto these first 5 principal components as features. We also included exon length and exon length mod 3 as features associated with each variant.
Variant Level
In order to consider the local sequence context of variants, we included spectrum kernel features representing the change in trinucleotide content induced by the variant 53 . For all 64 possible trinucleotides, we created a vector counting the number of occurrences in the alternative sequence and subtracted an equivalent vector for the reference sequence. The MaxEntScan reference score, alternative score and difference between the two were all used as features to quantify the strength of each exons' reference and alternative 5' and 3' splice site. SPIDEX scores 33 were downloaded directly from the Deep Genomics website on 7 April 2017. These scores can now be downloaded from Annovar (see URLs). Any variant not assigned a SPIDEX score was assigned a value of 0. We included 8 scores measuring evolutionary conservation, specifically, PhyloP 46way vertebrates, placental mammals, primates, PhyloP 100way vertebrates, PhastCons 46way vertebrates, placental mammals, primates and the PhastCons 100way vertebrates. Any base not annotated with a conservation score was assigned a value of 0. We also included the signed distance to the 5'ss and 3'ss splice site of the associated exon as features to measure base-pair importance.
Region Specific features
The 3' intronic S-CAP model includes a branchpoint feature modeled using LaBranchoR, a bi-directional LSTM (long short-term memory) model trained on the genome sequence surrounding experimentally validated branchpoint sites 42 . Specifically, we used the in silico mutagenesis scores available online (see URLs) as a feature.
We explicitly represented the strength of cryptic sites created by each variant using MaxEntScan 41 . In 3' intronic, 3' core, and exonic bins, we included a 3' cryptic splice site creation term and, in the exonic, 5' extended, 5' core, and 5' intronic bins, we included a 5' cryptic splice site creation term. For each variant, we scanned for the highest scoring splice site motif that overlaps the variant, excluding reference splice sites. We used as features the strength of the cryptic site, the change in the strength of the cryptic site induced by the variant, the distance from the reference splice site to the cryptic site and the difference in strength between the cryptic site and the reference splice site.
Model Training and Testing
We performed 5-fold cross-validation to train and identify a generalizable S-CAP model. 5-fold crossvalidation refers to splitting the data into 5 roughly equally sized parts (folds). All variants found in a single gene were included in the same fold to ensure that there was no leakage of feature information across the training and test sets. We then merged 4 of 5 sets to form a training dataset, trained the model on this training dataset and evaluated on the remaining fold to obtain an expected accuracy. We performed this process 5 times (each combination of 4 folds was merged together to form the training dataset) testing on the fold that was not included in the training dataset.
To train the S-CAP model, we used a Gradient Boosting Tree model implemented in the python 2.7.13 sklearn version 0.18.1 library and used the default parameters to reduce the chance of overfitting the model. After training 5 models during the cross-validation phase, we picked the median performing model as the final classifier. The ROC curves were built based on performance on the test set for this specific median model.
Comparison Metrics
We sought to compare our performance to those of other methods used to infer the importance / pathogenicity of noncoding variants. We evaluated the performance of each of the methods below by using the output score directly as a pathogenicity score. For SPIDEX, we negated the score, as is consistent with large negative scores having a larger impact on function and constraint, respectively. We report performances for all subsets where the method reported scores for at least 50% of variants. Variants where a method did not report a score are excluded from evaluation. CADD 11 v1.3 scores were downloaded from the CADD website (see URLs). SPIDEX 33 scores were downloaded directly from the Deep Genomics website on 7 April 2017. Any variant not assigned a SPIDEX score was assigned a default value of 0. LINSIGHT 30 scores were downloaded directly from the LINISGHT website (see URLs) on 7 April 2017. Any variants not assigned a LINSIGHT score was defaulted to be 0. Eigen v1.0 coding and Eigen v1.0 noncoding 29 Phred scores were downloaded from the Eigen website (see URLs). MutPredSplice 53 score were downloaded from the MutPredSplice website (see URLs).
As MutPred Splice was trained using some of the same data used to build S-CAP, a random train and test split of the pathogenic data would have resulted in the inclusion of variants in the test set that were used to train the MutPred Splice classifier. To ensure zero information leakage between the training and testing datasets, we carefully built a test set that excluded all MutPred Splice training data.
Recessive v. Dominant Classifiers
We developed separate classifiers for recessive and dominant acting variants in the 3' and 5' core splice site regions. We opted not to include dominant and recessive classifiers for the other 4 regions as we did not have a sufficient number of pathogenic variants to train and evaluate multiple models and, in our exploration, they made less of an impact. Intuitively, for core variants the molecular phenotype is obvious, a loss of splicing. This places the full burden on predicting if this change will result in disease, a task heavily dependent upon whether the variant acts via a recessive or dominant mechanism. Whereas in the other regions, the majority of possible variants have little impact on splicing, making predictions as to whether or not the variant will have an effect on splicing is the primary challenge, a task unrelated to inheritance mode.
When evaluating a patient, core variants observed as heterozygous are routed to the dominant classifier and variants observed to be homozygous are routed to the recessive classifier. Since there is no genotype information available for the labeled pathogenic and benign variants, we developed a framework to label variants as dominant or recessive based on their occurrence in a control population. We labeled pathogenic variants observed as heterozygous in the control population as likely recessive, because a single copy can be harbored with no major issues, and pathogenic variants never observed in the control population as likely dominant. Benign heterozygous variants that are never observed as homozygous in the healthy control population provide little information regarding their potential to cause a recessive acting disease. In this case, we tagged benign heterozygous variants never observed to be homozygous as dominant, and benign variants observed as homozygous as recessive. Additionally, as any variant on the X chromosome resembles a homozygous autosomal variant in males, all X chromosome variants were labelled as recessive.
We encoded whether each variant was considered dominant or recessive as a binary feature and trained a single gradient boosting tree model for each region. Then, we found two 95% true positive rate thresholds separately based on test sets of only dominant-tagged and only recessive-tagged variants.
Patient Datasets
Sequencing and diagnosis for all patients was performed by other laboratories. All patient data were downloaded by requesting access to the European Genome-Phenome Archive (EGA) and the database of Genotype and Phenotype (dbGaP) databases. Variant call files (VCFs) for 11 patients were submitted by the Deciphering Developmental Disorders (DDD) study in the European Genome-Phenome Archive (EGA) study EGAS00001000775. An additional 3 patient VCFs were submitted to the database of Genotype and Phenotype (dbGaP) study phs000655.v3.p1.
Data availability
S-CAP scores for all rare variants in the predefined splicing region in the human genome, along with the source code repository and final trained models for the S-CAP classifier, will be made available via the S-CAP website upon publication. Table 2 . High sensitivity thresholds after recalibrating each method. We retuned each existing method for each of Figure 1 's six regions by finding the smallest threshold that resulted in the correct classification of 95% of pathogenic variants from that region. S-CAP thresholds for all regions (including the dominant and recessive modes) are included in the last column. By definition with the high sensitivity thresholds each method will misclassify at most 5% of known pathogenic mutations, but their effectiveness at correctly classifying benign variants and reducing the number of patient VUS will vary greatly. Table 3   Table 3 . Causative variants in each patient and pathogenicity predictions. Each row describes a single patient, their underlying disease, causative variant and its zygosity, the region of the genome in which it is located, and the score and percentile each method assigns to the variant. The percentile was computed by measuring the fraction of variants in the same region with a score less than the score assigned to the causative variant. The 99 th percentile denotes that 99% of variants in that region have a score less-pathogenic than the one we are observing We built two sets of rare variants near exon boundaries that have no effect on the annotated coding sequence: (A) a set of likely benign variants from the Genome Aggregation Database (gnomAD) and (B) a set of putatively pathogenic variants from the Human Gene Mutation Database (HGMD) and ClinVar. We developed a simple model to ascertain the effect of these variants on splicing, using MaxEntScan to assess if a variant created a cryptic splice site (SS) or disrupted the reference splice site, and LaBranchoR in silico mutagenesis scores to assess if a variant disrupted a branchpoint (BPT). In (A) and (B), we plot the aggregate counts of each variant set as a function of position relative to the nearest splice site, colored by their putative effect. Nearly 97% of pathogenic variants in the splicing region (as defined in the text) are predicted to have a putative deleterious effect on splicing, as compared to only 18% of benign variants. (C) We split the variants into different regions with largely homogenous function. The majority of known pathogenic variants (and the easiest ones to detect) are found in the 3' and 5' core splice site For each method, 1000 threshold points were determined by evenly spanning the range from the minimum to the maximum score observed for the method. A true positive rate and false positive rate were determined for each threshold value and used to build the receiver operating characteristic (ROC) curve. We compared to the next best method in each region and found that S-CAP performs 17.2% better in the 3' intronic region (A), 26.6% better in the 3' core sites (B), 20.9% better in the exonic region (C), 20.7% better in the 5' core sites (D), 15.5% better in the 5' extended region (E) and 14.4% better in the 5' intronic region (F). S-CAP outperforms existing metrics in all regions whereas none of the existing methods consistently outperforms the others. Performance of S-CAP compared to MutPred Splice. MutPred Splice is a computational method for predicting the pathogenicity of exonic synonymous variants. MutPred Splice was trained by its authors using a subset of the pathogenic data used to train/test S-CAP. As a result, we need to independently test MutPred Splice on a set of variants that was not used in its training. This test set comprises rare synonymous variants from HGMD added to the database in 2013 or later. On this set S-CAP improves on MutPred Splice by 5.7% when comparing the overall AUC. S-CAP performs especially well in the high sensitivity domain and improves on the MutPred Splice hsr-AUC by 204%.
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